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Abstract: Despite its high prevalence and individual as well as societal burden, migraine 
remains underdiagnosed and undertreated. In recent years, the options for the management 
of migraine patients have greatly expanded. A number of drugs belonging to various pharma-
cological classes and deliverable by several routes are now available both for the acute and 
the preventive treatments of migraine. Nevertheless, disability and satisfaction remain low in 
many subjects because treatments are not accessible, not optimized, not effective, or simply not 
tolerated. There is thus still considerable room for better education, for more efﬁ  cient therapies 
and for greater support from national health systems. In spite of useful internationally accepted 
guidelines, anti-migraine treatment has to be individually tailored to each patient taking into 
account the migraine subtype, the ensuing disability, the patient’s previous history and present 
expectations, and the co-morbid disorders. In this article we will summarize the phenotypic 
presentations of migraine and review recommendations for acute and preventive treatment, 
highlighting recent advances which are relevant for clinical practice in terms of both diagnosis 
and management.
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Introduction
The Global Burden of Disease study conducted by the the World Health Organization in 
2000 and reported in the World Health Report 2001 shows that mental and neurological 
disorders collectively account for 30.8% of all years of healthy life lost to disability 
and, among them, migraine for 1.4%, which places it in the top 20 causes of disability 
worldwide (Leonardi et al 2005).
The most prevalent neurological disorder is thus migraine, with an estimated 
41 million cases in Europe. The total cost of migraine in Europe (including direct 
costs of medical care and indirect costs due to lost productivity) is estimated 
at €27 billion/year (Andlin-Sobocki et al 2005). Migraine seems to entail a cost of 
€590 per year per patient in Western European countries (Berg and Stovner 2005). This 
is in line with data from the US, where calculated costs (cost basis of 2004 including 
inﬂ  ation converted to Euros) were €8 to 23 billion/year (Clouse and Osterhaus 1994; 
Hu et al 1999; Osterhaus et al 1992).
Although migraine is one of the commonest reasons for patients to consult their 
doctor and despite its enormous impact, it is still under-recognized and under-treated 
(Diamond et al 2007). This has various reasons. On the one hand, there are no 
biological markers to conﬁ  rm the diagnosis and many doctors lack knowledge, time, 
interest, or all three, to manage migraineurs. On the other hand, there is no cure for 
migraine and, although effective therapies do exist, they have only partial efﬁ  ciency 
or are not accessible to all. As a result, a proportion of affected individuals do not 
seek (anymore) medical help. We hope that this article, in which we will focus on Neuropsychiatric Disease and Treatment 2008:4(6) 1044
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migraine in adulthood, will help to convince that migraineurs 
should certainly accept their disorder and cope with it, but 
not resign themselves.
Epidemiology
The most recent European and American population-based 
studies in adults, all using International Headache Society 
(IHS) criteria, have found very similar prevalence rates 
for migraine in adults (see Steiner et al 2003; Stovner et al 
2007). A recent review of available population-based studies 
showed a global prevalence among adults of current migraine 
of 11% (Stovner et al 2007). The male:female ratio for 
migraine among adults varies from 1:2 to 1:3 and women 
have more migraine without aura than migraine with aura 
(Zwart et al 2004; Rasmussen 2001; Jensen and Stovner 2008). 
In the US Lipton et al (2001, 2007) have found a stable 1-year 
prevalence of 12%. Studies in general populations agree that 
it is most common for migraineurs to have an average attack 
frequency of one or two per month. In clinical samples the mean 
frequency of attacks is obviously higher. A large number of 
headache sufferers with features of migraine fail to meet all IHS 
criteria for migraine but do so for probable migraine (attacks 
and/or headache missing one of the criteria A-D needed for 
migraine without aura, see Table 1). The 1-year prevalence 
for probable migraine was 14.6% (15.9% in women, 12.6% in 
men) in a recent study (Patel et al 2004).
In a meta-analysis of 2612 patients suffering from 
Medication Overuse Headache (MOH), migraine was the 
Table 1 Diagnostic criteria for migraine with and without aura and for chronic migraine
Migraine without aura (ICHD-II code 1.1)
A.  At least 5 attacks fulﬁ  lling criteria B-D
B.   Headache attacks lasting 4–72 hours (untreated or unsuccessfully treated)
C.   Headache has at least two of the following characteristics:
    1. unilateral location
   2.  pulsating  quality
    3. moderate or severe pain intensity
    4. aggravation by or causing avoidance of routine physical activity (eg, walking or climbing stairs)
D.   During headache at least one of the following:
    1. nausea and/or vomiting
    2. photophobia and phonophobia
E.   Not attributed to another disorder
Migraine with aura (ICHD-II code 1.2.1)
A.  At least 2 attacks fulﬁ  lling criteria B–D
B.  Aura consisting of at least one of the following fully reversible features, but no motor weakness:
    1. visual symptoms including positive features (eg, ﬂ  ickering lights, spots or lines) and/or negative features (ie, loss of vision)
    2. sensory symptoms including positive features (ie, pins and needles) and/or negative features (ie, numbness)
    3. dysphasic speech disturbance
C.   At least two of the following:
    1. homonymous visual symptoms and/or unilateral sensory symptoms
    2. at least one aura symptom develops gradually over 5 minutes and/or different aura symptoms occur in succession over 5 minutes
    3. each symptom lasts 5 and 60 minutes
D.   Headache fulﬁ  lling criteria B-D for 1.1 Migraine without aura begins during the aura or follows aura within 60 minutes
E.   Not attributed to another disorder
Chronic migraine (ICHD-II code 1.5, modiﬁ  ed criteria of the ICHD-II)
A.   Current or prior headache fulﬁ  ls criteria for 1.1 migraine without aura
B.   Headache on 15 days a month
C.  At least 8 headache days a month for the previous 3 months fulﬁ  lling at least one of he following:
    1. Criteria C and D for 1.1 migraine without aura
    2. Criteria C and D for 1.1 migraine without aura with the exception of a single sub-criterion, and not meeting criteria for 2.1 tension-type headache
    3. Headache that the patient believes to be migraine and is relieved by a 5-HT1B/1D receptor agonist
D.   Not attributable to another disorder, including medication overuse headacheNeuropsychiatric Disease and Treatment 2008:4(6) 1045
Migraine management
primary headache in 65% of patients, tension-type headache 
in 27% and all other headache combined in 8% (Diener 
and Dahlof 1999). About 1%–2% of the general population 
suffer from chronic daily headache associated with MOH 
(see Obermann and Katsarava 2007 for a recent review).
Phenotype
The Headache Classiﬁ  cation with operational diagnostic 
criteria established by the International Headache Society 
(IHS) in 1988 was an important milestone for the clinical 
diagnosis and is accepted world-wide. Its second edition 
(ICHD-II) (2004) has fine tuned the classification of 
migraine types and settled the important issue of frequent, 
almost daily headache and medication overuse headache. 
Migraine is deﬁ  ned as a recurrent headache presenting in 
attacks which last between 4 and 72 hours. Typical features 
of the headache are unilateral location, pulsating quality, 
moderate or severe intensity, aggravation by routine physical 
activity and association with nausea and/or photophobia and 
phonophobia. The headache may be preceded in 15% to 
20% of patients by an aura, so-called migraine with aura. 
The aura may last between 5 and 60 minutes. The most 
common type is visual aura, causing scotomas, teichopsia, 
fortiﬁ  cation spectra, and photopsias. It can also comprise 
other neurological symptoms such as focal paraesthesias, 
speech disturbances and, in hemiplegic migraine, a unilat-
eral motor deﬁ  cit (Vincent and Hadjikhani 2007). Chronic 
migraine, formerly known as transformed migraine, is diag-
nosed when a patient has migraine on 15 or more days each 
month over a period of at least 3 months (recently modiﬁ  ed 
ICHD-II criteria, Olesen et al 2006). Patients usually have 
a history of migraine attacks that gradually worsen over a 
period of months or years (see Table for ICHD-II diagnostic 
criteria). Medication-overuse headache (MOH) is deﬁ  ned 
(ICHD-II code 8.2) as a headache presenting on at least 
15 days per month associated with regular overuse of one 
or more of the following: triptans, ergotamines, opioids or 
analgesics. These criteria have been revised, eliminating the 
headache caracteristics as diagnostic criterion and adding a 
new subform – MOH attributed to a combination of acute 
medications (Silberstein et al 2005; Olesen et al 2006).
The heterogeneity of the clinical phenotype of migraine is 
underestimated. Despite a common diagnostic denominator, 
some clinical features such as type of aura symptoms, pain 
intensity, presence of prodromes, coexistence of migraine 
with and without aura or associated symptoms such as vertigo, 
may characterize subgroups of patients bearing different 
underlying pathophysiological and genetic mechanisms.
Pain intensity can help to distinguish migraine without 
aura from tension-type headache (TTH). The TTH diagnosis, 
however, is mainly based on the absence of features found 
in other headache types such as migraine. It is thus above all 
a “featureless” headache characterised by nothing but pain 
in the head (Fumal and Schoenen 2008). Among subjects 
in the general population classiﬁ  ed as TTH sufferers, a 
non-negligeable proportion has clinical features suggestive 
of migraine, like headache aggravation by routine physical 
exercise, pulsating quality, anorexia, photophobia, unilateral 
headache or nausea (Rasmussen et al 1991; Schoenen and 
Wang 1997). There is evidence therefore that some patients 
with mild migraine without aura are misdiagnosed as 
TTH (Fumal and Schoenen 2008).
In migraine, premonitory symptoms and trigger factors 
are manyfold and they may vary between patients and during 
the disease course. The most frequently reported premonitory 
symptoms are fatigue, phonophobia, and yawning (Schoonman 
et al 2006). Concerning trigger factors, the most common ones 
are stress, the perimenstrual period, and alcohol (Karli et al 
2005). Overuse of acute anti-migraine drugs, in particular 
of combination analgesics and ergotamine, is another 
underestimated aggravating factor.
There is a complex interrelation between migraine 
and depression, both conditions being highly co-morbid 
(Breslau et al 2003). Episodic vertigo without other signs of 
basilar-type migraine might belong to the migraine phenotype 
(Eggers 2007).
Genotype
The common migraine phenotypes appear to be complex 
genetic disorders, where additive genetic effects (susceptibility 
genes) and environmental factors are interrelated (Stewart et al 
1997). Some studies suggest different liability loci for migraine 
headache and aura (Haan et al 2005). Genetic abnormalities 
may also induce incidental subclinical dysfunctions such as 
for instance a reduced neuromuscular junction safety factor 
(Ambrosini et al 2001) or subtle cerebellar hypermetria 
(Sandor et al 2001a). Various gene polymorphisms were found 
to be more prevalent in migraineurs than in controls (Haan et al 
2005). Their precise role remains to be determined; some of 
them may not be speciﬁ  c to migraine, but they could increase 
susceptibility to the disorder and induce endophenotypic 
vulnerability markers.
Heritability of migraine is a useful tool in clinical 
practice for helping to explain to patients that they were 
born with a liability for headache; by establishing that their 
parents also had headaches, or by pointing out that trigger Neuropsychiatric Disease and Treatment 2008:4(6) 1046
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factors do not produce headache universally, doctors can 
offer an explanation of migraine mechanisms, which is an 
expectation many patients consider as a priority when they 
consult (Goadsby 2006). The genetic load, ie, the “migraine 
susceptibility genes”, can be cumulative and determines a 
critical attack threshold which can be modulated by external 
(psychosocial stress, preventive therapies ...) and internal 
factors (hormonal status, anxiety …). Triggers, such as 
alcohol, are more likely to induce an attack when the migraine 
threshold is lowered, for instance in the perimenstrual period 
in many female migraineurs. If the threshold is reached, the 
cellular and molecular cascade leading to activation of the 
trigeminovascular system is ignited in the brain and/or brain 
stem. The genetic load is likely to determine the severity of 
the migrainous disorder, as well as some its complications 
like chroniﬁ  cation by medication overuse. Some subjects will 
remain attack-free despite have some liability genes, while 
others with a less favourable genotype will continue to suffer 
in spite of therapeutic interventions (Sándor et al 2001b).
Important issues for non-headache 
specialists
Caring for a patient complaining of headaches requires above 
all a thorough history taking and physical examination that 
includes a neurological examination. To evaluate the likelihood 
of a secondary, symptomatic headache, the most crucial feature, 
besides clinical examination, is the duration of the headache 
history. Patients with a short history require prompt attention 
and may need quick complimentary investigations, while 
those with a longer headache history generally require time 
and patience rather than speed and imaging (Goadsby 2006). 
Red ﬂ  ags that should alert to the possibility of a secondary 
headache include pain of sudden onset, fever, marked change 
in pain character or timing, neck stiffness, pain associated 
with neurological disturbances, such as cognitive dysfunction 
or weakness, and pain associated with local tenderness, for 
example of the superﬁ  cial temporal artery (Silberstein and 
Rosenberg 2000a). Patients with recent onset headache or 
with neurological signs require at the least brain imaging with 
computed x-ray tomography or magnetic resonance imaging.
Pathophysiology
The present consensus is that both neuronal and vascular 
components are relevant in migraine and most probably 
interrelated (Schoenen 1998; Sándor et al 2001b; Goadsby 
et al 2002). The neuronal structures involved are the cerebral 
cortex, the brainstem (periaqueductal gray matter, aminergic 
nuclei) and the peripheral as well as the central components 
of the trigeminovascular system. The sequence of activation 
and the relative role of these structures are still controversial. 
As migraine management is the main topic of this review 
article, we will not further discuss pathophysiology, which is 
covered in more detail elsewhere (see reviews by Moskowitz 
2007; Goadsby 2007a).
Management of migraine
Besides drug and non-drug treatments, migraine management 
includes a seminal aspect which receives little or no 
consideration during medical teaching: patient information 
and education. This includes, as mentioned above, information 
about the mechanisms, potential complications and treatment 
options of migraine, but also education about monitoring of 
disease activity using a headache diary, coping strategies, 
ways to change life style and to avoid triggers, as well as 
appropriate and timely use of drug treatments and their 
possible adverse effects.
Traditionally, migraine treatment is subdivided into acute 
strategies to interrupt attacks and preventive ones to prevent 
attack occurrence. There is substantial room for improvement 
in efﬁ  cacy, tolerance and safety of both acute and, even more 
so, preventive drug treatments. Non drug therapies with 
proven efﬁ  cacy in migraine include blood pulse volume, skin 
temperature or EMG biofeedback, and acupuncture.
Acute treatment
In many patients with infrequent attacks, treatment at the 
time of an attack may sufﬁ  ce. Once the patient’s prefer-
ence and eventual contraindications have been taken into 
consideration, the following (Goadsby et al 2002) are key 
features for the successful use of acute anti-migraine drugs:
(i) the drug should be taken as soon as the headache 
component of the attack is recognized,
(ii) the dose of drug should be high enough (this is 
particularly important for NSAIDs, which need high 
dosing, eg, 600 to 1200 mg for ibuprofen) to be fully 
effective in migraine,
(iii) the co-administration of anti-emetic or pro-kinetic drugs 
(eg, domperidone, metoclopramide) is likely to facilitate 
the absorption of the primary drug and thus to ameliorate 
speed of action and efﬁ  cacy,
(iv) overuse of any acute anti-migraine drug may induce 
chroniﬁ  cation and medication overuse headache; their 
intake should thus be restricted; we recommend no more 
than one day of triptans, ergotamine or combination 
analgesics and two days of simple analgesics or NSAIDs 
per week,Neuropsychiatric Disease and Treatment 2008:4(6) 1047
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(v) ﬁ  nally, it is important to remember, and well known 
to sufferers, that severity and response to treatment 
vary between attacks; patients may therefore require a 
prescription for several drugs of increasing potency to 
manage their attacks, allowing for a combined “stratiﬁ  ed” 
(choice of drug according to severity of attack) and 
“step-wise within attack” (drugs of increasing potency 
during the attack) strategy.
Non-speciﬁ  c anti-migraine drugs
Drugs of ﬁ  rst choice for mild or moderate migraine attacks 
are analgesics and NSAIDs. Evidence of efﬁ  cacy in migraine 
treatment has been obtained in at least one placebo-controlled 
trial for acetylsalicylic acid (up to 1000 mg), paracetamol 
(1000 mg), phenazone (1000 mg), metamizol (1000 mg), 
ibuprofen (200 to 800 mg), diclofenac (50 to 100 mg) and 
tolfenamic acid (200 mg) (see Evers et al 2006 for a recent 
review). Several trials have shown superiority of ibuprofen 
(even at rather low doses of 200 to 400 mg) over aspirin 
or paracetamol in mild and moderate attacks (Nebe et al 
1995; Diener et al 2004a). As ibuprofen also carries a lower 
risk of gastro-intestinal complications than ketoprofen, 
diclofenac or naproxen (Langmann et al 1994; Garcia 
Rodriguez et al 1994), it can be considered as the 1st choice 
NSAID (Figure 1). It remains to determine whether the more 
expensive Cox-2 inhibitors like celecoxib have an advantage 
over ibuprofen besides better gastric tolerance. Advising 
NSAIDs instead of analgesics seems also relevant in terms 
of prevention of medication overuse headache. Combining 
analgesics and/or NSAIDs to caffeine increases their efﬁ  cacy 
(Di Monda et al 2003; Diener et al 2005; Goldstein et al 
2006), but it increases also the risk of inducing medication 
overuse headache in susceptible patients with frequent 
attacks.
Speciﬁ  c anti-migraine drugs
The advantages of ergotamine tartrate is its low cost, long 
duration of action and long clinical experience The major 
disadvantages are the lack of evidence regarding its effective 
doses, its potent and sustained generalized vasoconstrictor 
effect, and the fact that it can induce drug overuse headache 
very fast and in quite low doses, especially when combined to 
caffeine (Evers et al 1999). There is therefore an international 
consensus since the avenue of triptans that there is no 
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Figure 1 An algorithm for “stratiﬁ  ed” and “step-wise within attack” treatment of migraine attacks, inspired from personal experience and the Belgian pharmacoeconomic 
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evidence to continue to use ergot derivatives, except in 
patients who are already using them with excellent results 
and tolerance (Tfelt-Hansen et al 2000a).
Parenteral dihydroergotamine (DHE), on the contrary, is 
an effective treatment of migraine attacks (see meta-analysis 
by Colman et al 2005). It can be used as subcutaneous, 
intramuscular or intravenous injections. The latter may be 
useful in prolonged and/or refractory attacks, but must be 
limited to in-patients. The efﬁ  cacy of intranasal DHE is inferior 
to that of intranasal sumatriptan (Boureau et al 2000).
During the last decade, the advent of highly effective 
5-HT1B/1D agonists, the triptans, has been a major breakthrough 
in the attack treatment. Triptans are able to act as 
vasoconstrictors via vascular 5-HT1B receptors and to inhibit 
neurotransmitter release at the peripheral as well as at central 
terminal of trigeminal nociceptors via 5-HT1D/B receptors 
(Humphrey and Goadsby 1994). The site of action relevant 
for their efﬁ  cacy in migraine is still a matter of controversy; 
possibly their high efﬁ  cacy rate is due to their capacity of 
acting at all three sites contrary to other anti-migraine drugs. 
Sumatriptan, the pioneer triptan, was followed by several 
second generation triptans (zolmi-, nara-, riza-, ele-, almo-, 
frovatriptan), which were developed to correct some of the 
shortcomings of sumatriptan.
The comparison of several randomized placebo-controlled 
trials performed with triptans, including the large meta-analysis 
by Ferrari et al (2001), indicates that the subcutaneous 
form of sumatriptan (6 mg) has the best efﬁ  cacy and the 
most rapid speed of action whatever outcome measure is 
considered. Differences between the oral triptans do exist 
for some outcome measures, but their clinical signiﬁ  cance is 
questionable and in practice each patient has to ﬁ  nd out which 
triptan gives him the best satisfaction.
At present, the major reason for not considering triptans 
as ﬁ  rst choice treatments for migraine attacks is their high 
cost, and in vulnerable patients their cardiovascular side 
effects (Dodick et al 2004). However, stratifying care by 
prescribing a triptan to the most disabled patients may be 
cost-effective. In severely disabled migraineurs the efﬁ  cacy 
rate of injectable sumatriptan for pain-free at 2 hours is 
twice/thrice that of ergot derivatives or NSAIDs taken at 
high oral doses (Schoenen et al 1994) and of iv acetylsalicylic 
acid lysinate (Diener et al 1999). The therapeutic gain tends 
to be clearly lower for simple analgesics or NSAIDs than 
for the oral triptans, when severe attacks are considered. 
As expected, however, triptans have not solved the patients’ 
problems, and for the oral forms ± 30% of attacks do not 
respond and when there is a response at 2 hours disabling 
symptoms may persist in another ± 30%. To improve the 
therapeutic score of oral triptans, they can be combined with 
an NSAID which increases pain-free rates and decreases 
recurrence rates, a beneﬁ  t demonstrated in placebo-controlled 
trials for sumatriptan-naproxen sodium (Brandes et al 2007) 
and almotriptan- aceclofenac combinations (Schoenen 
et al 2008).
As a general rule, opiates have no place in the management 
of migraine attacks, because they favour medication overuse 
in susceptible patients and other effective drugs do exist. 
Exceptionally, however, they can be used with caution in some 
patients orally combined with analgesics or as injections for 
resistant disabling attacks.
The interrelation between headache response, return to 
normal functioning and treatment acceptability is a clinically 
and pharmaco-economically important consideration in the 
selection of an optimal migraine therapy. Davies et al (2000) 
studied the relationship between clinical trial end points 
and patients’ satisfaction with acute migraine treatments: 
when pain-free at 2 hours post-dosing, more than 90% of 
patients declared they were satisﬁ  ed with the treatment; when 
mild pain persisted at 2 hours, 60% to 80% did so and the 
proportion dropped to 10% when pain remained moderate 
or severe. Rapid headache relief and return to normal function 
are the main factors correlating with treatment acceptability 
(Pradel et al 2006).
Figure 1 shows an algorithm for a “stratified” and 
“step-wise within attack” strategy for the treatment of 
migraine attacks, inspired from the available literature 
(see reviews by Evers et al 2006 and Goadsby et al 2006) 
as well as from personal experience and the Belgian 
pharmaco-economic situation.
Prophylactic therapy in migraine
Prophylactic anti-migraine treatment has to be individually 
tailored to each patient taking into account his disability, 
demands, expectations and previous history, the migraine 
subtype and the co-morbid disorders.
Drug treatments
Except for methysergide which was designed on basis of 
the “hyper-serotonin” theory of the migraine attack, the 
major prophylactic anti-migraine drugs were not developed 
speciﬁ  cally for migraine and their efﬁ  cacy is thus based 
on empirical data. As a matter of fact, they belong to 
very different pharmacological classes and their mode 
of action in migraine may be remote from their principal 
pharmacological target, which is further underlined by the Neuropsychiatric Disease and Treatment 2008:4(6) 1049
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fact that not all agents belonging to a class have proven 
anti-migraine efﬁ  cacy. The 4 major classes are beta-blockers 
(but only those devoid of intrinsic sympathicomimetic 
activity), anti-convulsants (but only some like valproate 
and topiramate), serotonin receptor blockers (mainly 
methysergide), Ca2+ antagonists (but only ﬂ  unarizine and 
verapamil) and, to a lesser degree, tricyclics. In recent 
years, drugs with totally different pharmacological actions 
were found effective in migraine prophylaxis, for example, 
metabolic enhancers like riboﬂ  avin (Schoenen et al 1998) and 
co-enzyme Q10 (Sándor et al 2005), angiotensin converting 
enzyme (lisinopril) (Schrader et al 2001) or receptor 
(candesartan) inhibitors (Tronvik et al 2003), magnesium 
salts (Peikert et al 1996) or herbs such as petasites (butterbur) 
(Diener et al 2004; Lipton et al 2004) and tanacetum 
parthenium (feverfew) (Diener et al 2005). Evidence-based 
medicine criteria are difﬁ  cult to apply comprehensively to 
preventive pharmacotherapy because large and high quality 
randomised controlled trials do not exist (for old drugs 
such as amitriptyline) or are sparse (for low proﬁ  t making 
drugs like most neutriceuticals) and because comparative 
trials are rare. A major drawback of the ﬁ  rst group of drugs, 
which have on average a 50% to 60% efﬁ  cacy score, is their 
mediocre efﬁ  cacy/adverse effects proﬁ  le. Adverse effects are 
inexistent or trivial with most drugs of the second group, but 
their efﬁ  cacy score is lower (30% to 50%) and onset of action 
slower (Schoenen et al 2004) (Figure 2).
The decision to install a prophylactic treatment has to be 
carefully discussed with the patient. There is no uniformly 
accepted criterion for the timing of a preventive treatment. 
According to recent guidelines proposed by a task force of 
the European Federation of Neurological Societies (EFNS) 
(Evers et al 2006), prophylactic drug treatment should be 
considered and discussed with the patient when at least one 
of the following conditions is fulﬁ  lled: (i) the quality of life, 
business duties, or school attendance are severely impaired; 
(ii) the frequency of attacks per month is two or higher; 
(iii) migraine attacks do not respond to acute drug treatment; 
and (iv) frequent, very long, or uncomfortable auras occur.
Headache diaries are useful tools both for patients and 
doctors to monitor the response to preventive therapy. Each 
drug, except neutriceuticals, should be started at a low dose, 
and gradually increased up to the minimal efﬁ  cient dose 
to minimize side effects. Patients should be informed that 
several weeks or months of treatment may be required to 
reach maximum beneﬁ  t and that the ﬁ  rst drug that we try is 
not always the right one. According to international criteria 
for controlled drug trials (Tfelt-Hansen et al 2000b), migraine 
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prophylaxis is regarded as successful if frequency of attacks 
per month is decreased by at least 50% within 3 months, but 
in daily practice, patients’ satisfaction is the gold standard. 
If the prescribed preventive is efﬁ  cient without causing 
cumbersome side effects, it is continued for 6 to 8 months. 
After this time period, if the patient judges his amelioration 
as sufﬁ  cient and agrees, we gradually and slowly decrease 
the dose over 6 to 8 weeks before stopping the treatment if 
there is no loss of the clinical beneﬁ  t during the tapering 
phase. If there is a clinical aggravation during tapering, the 
previous (or initial) dose is reinstaured. If the treatment is 
not successful, dosing of the medication should be increased 
up to the maximum allowed or an alternative preventive 
treatment should be chosen (D’Amico and Lantéri-Minet 
2006). The determinant of patients’ compliance with an 
anti-migraine drug is a complex equation depending on a 
high efﬁ  cacy/tolerance ratio which is a crucial measurable 
variable, but also on irrational interfering factors, such as 
expectation, knowledge, prejudices and concerns about the 
drug. Nonetheless, as shown in some studies, patients rate 
efﬁ  cacy the most important aspect in preventive therapy and 
prefer treatment options with higher efﬁ  cacy rates even if 
adverse events occur and a more frequent dosing schedule 
is needed (Peres et al 2007).
The EFNS task force (Evers et al 2006) proposes 
beta-blockers (metoprolol and propranolol), calcium channel 
blockers (ﬂ  unarizine) and anti-convulsants (valproic acid 
and topiramate) as 1st choice preventive anti-migraine 
treatments, while amitriptyline, bisoprolol, petasites 
and naproxen are drugs of second choice because they 
have less evidence of efficacy and/or more side effects 
than drugs of ﬁ  rst choice). It classiﬁ  es as drugs of third 
choice gabapentin, riboflavin, tanacetum parthenium, 
coenzyme Q10, candesartan, lisinopril, magnesium, 
and methysergide. One can object to this proposal that 
there is no evidence that the beta-blockers effective in 
migraine have different efﬁ  ciency and that unwanted beta 2 
adrenoreceptor-related bronchoconstrictor and central nervous 
system effects do not favour propranolol as ﬁ  rstchoice within 
this class. There is also no objective reason to prefer petasites 
over riboﬂ  avin or feverfew or candesartan. Amitriptyline is 
another problematic classiﬁ  cation, as there is no proof for its 
efﬁ  cacy in uncomplicated migraine from a controlled study 
fulﬁ  lling modern methodological requirements (Bendtsen 
2003). It is nonetheless a popular drug in the USA where a 
Headache Consortium (Silberstein et al 2000) has even pro-
posed it as a ﬁ  rst choice drug, a proposal probably based on the 
fact that American headache experts treat at majority patients 
with migraine complicated by medication overuse and/or 
tension-type headache in whom amitriptyline is useful, rather 
than on its efﬁ  cacy/adverse effect proﬁ  le in migraine per se.
Lamotrigine is up to now the only preventive drug which 
has been shown effective for migraine auras (D’Andrea et al 
1999; Lampl et al 2005) but not for migraine without aura 
(Steiner et al 1997; Gupta et al 2007).
To summarize, we prefer to separate the anti-migraine 
preventive drugs into 2 groups, a group of “stringent” drugs 
characterized by relatively high efﬁ  cacy, rapid onset of action 
and high adverse effect incidence, and a “less stringent” 
group with somewhat lower efﬁ  cacy, speed of action but also 
clearly fewer side effects (Table 2). It seems obvious to start 
prophylaxis in patients with relatively low attack frequency 
(2 to 4/month) or with rare refractory attacks with a drug 
belonging to the “less stringent” group. We give preference 
to riboﬂ  avin because of its excellent efﬁ  cacy/side effect 
proﬁ  le and inform patients that the effect does not reach 
maximum before 6 to 8 weeks of treatment. Combining 
riboﬂ  avin to metoprolol or bisoprolol allows to keep the 
beta-blocker at a low, well tolerated dose, and has a patho-
physiologic rationale (see above). Because of its excellent 
tolerance, riboﬂ  avin is also a ﬁ  rst choice drug in children 
and adolescents, and, if anti-migraine prophylaxis is needed, 
during pregnancy (see below). In patients with more frequent 
attacks (4/month), a more rapidly acting drug is warranted 
such as valproate or topiramate. If these drugs fail, a trial of 
verapamil or methysergide or a sartan (a RCT exists only for 
candesartan, but in our clinical experience other sartans can 
be effective) is worthwhile before deciding to prescribe a 
combination of stringent anti-migraine drugs like topiramate 
and a beta-blocker. If several monotherapies are ineffec-
tive, combinations of ﬁ  rst-line drugs should be tried before 
advancing to drugs of second choice, which are associated 
with more adverse effects or have less well-established 
prophylactic properties (Schürks et al 2008). There is up to 
now no convincing evidence that gabapentin or other new 
generation anti-convulsants like levetiracetam have a place 
in the anti-migraine armamentarium. Lamotrigine is the most 
efﬁ  cient drug in patients who have frequent attacks of migraine 
with aura and no or almost no attacks without aura. If these 
attacks are not frequent, a trial with riboﬂ  avin is worthwhile 
(Figure 3). If migraine is co-morbid with hypertension, a sartan 
is an obvious excellent choice for preventive treatment.
Botulinum toxin
All large randomized controlled trials of pericranial injections 
of botulinum toxin A (BTX-A) as a preventive treatment have Neuropsychiatric Disease and Treatment 2008:4(6) 1051
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failed to show superiority over placebo in episodic migraine 
and in tension-type headache (Silberstein et al 2005; Mathew 
et al 2005; Relja et al 2007; review by Delstanche and 
Schoenen 2006). It remains to be determined whether there 
is a niche for botulinum toxin A in subtypes of migraine such 
as chronic migraine for which two trials are ongoing.
Non-drug therapies
Several non-drug therapies have proven efﬁ  cacy in migraine 
prophylaxis. A recent meta-analysis (total of 55 studies) 
showed that biofeedback signiﬁ  cantly and substantially 
reduces the pain and psychological symptoms of highly 
chroniﬁ  ed patients within the scope of only 11 sessions, 
and with a favourable long-term outcome (Nestoriuc 
and Martin 2007). Blood-volume-pulse feedback yielded 
higher effect sizes than peripheral skin temperature 
feedback and electromyography feedback. Another meta-
analysis (Trautmann et al 2006) also provided evidence 
for the efficacy of psychologically based interventions 
(relaxation training, biofeedback and cognitive-behavioural 
therapy) in children and adolescent.
Acupuncture was found effective for migraine prophylaxis 
in several recent studies that seem methodologically appropriate 
in terms of modelization and statistical analysis (according to 
modern standards of trial design), but there still remains some 
controversy. In a multicenter, randomized controlled trial of 
160 migraineurs (Facco et al 2007), true acupuncture had a 
signiﬁ  cant and clinically relevant effect over no treatment 
(waiting list). In two recent studies the beneficial effect 
acupuncture was numerically similar to that of standard drug 
treatments such as beta-blockers (Streng et al 2006; Diener et al 
2006). Surprisingly, however, traditional acupuncture was not 
superior to sham acupuncture (Linde et al 2005; Diener et al 
2006), although both were superior to a waiting list arm. This 
suggests that needling points and other aspects considered 
relevant for traditional acupuncture are not relevant for 
treatment effect in migraine and that high levels of expectation 
with acupuncture may bias outcome.
Table 2 Preventive treatments in migraine
Agents and doses Selected adverse events
“Stringent” drugs
β-blockers (q.d.) 
  Propranolol: 40–160 mg bisoprolol: 
  2.5–10 mg Metoprolol: 50–200 mg
Reduced energy, tiredness, postural hypotension, 
bronchoconstriction,
Valproic acid/sodium valproate 
  500–1000 mg qd 
 (sustained  release)
Sedation, nausea, weight gain, tremor, hair loss, 
Liver toxicity , teratogenicity
Topiramate 
  25–100 mg bid
Paresthesias, fatigue, dysgeusia, nausea, 
cognitive dysfunction, depression
Flunarizine 
  5–10 mg qd
Weight gain, depression, drowsiness, parkinsonism
Methysergide 
  1–4 mg bid
Drowsiness, leg cramps, weight gain, 
Fibrosis (except if 1 month drug holiday every 6 months)
Amitriptyline 
  25–75 mg qd
Weight gain, dry mouth, sedation, drowsiness
“Less stringent” drugs
Riboﬂ  avin 
  400 mg qd
Coenzyme Q10 
  100 mg tid
Lisinopril 
  10–20 mg q.d.
Cough
Candesartan 
  16 mg qd
Magnesium 
  24–30 mmol qd
Abdominal cramps, diarrhea
Petasites (butterbur)
Tanacetum parthenium (feverfew)Neuropsychiatric Disease and Treatment 2008:4(6) 1052
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Speciﬁ  c situations
Menstrual migraine
The International Headache Society Classification of 
Headache Disorders (ICHD) includes speciﬁ  c deﬁ  nitions 
for pure menstrual migraine (code ICHD-II A1.1.1) and 
menstrually related migraine (code ICHD-II A1.1.2). 
Menstrual attacks are most likely to occur on the 2 days 
preceding menstruation and the ﬁ  rst 3 days of bleeding 
(see MacGregor 2007a for a review). The acute treatment of 
menstrual attacks is not fundamentally different from that of 
non-menstrual attacks, except that one can try a short term 
prevention for menstrual attacks as they are predictable, and 
that these attacks are frequently of longer duration, needing 
a combination of triptans and NSAIDs.
Short term prophylaxis can be performed with NSAIDs, 
like ibuprofen (800 mg long acting qd or 300 mg bid) or 
naproxen (550 mg qd or bid) perimenstrually (Sargent 
et al 1985; Facchinetti et al 1989; Szekely et al 1989 and 
Nattero et al 1991), or with triptans (Newman et al 2001; 
Silberstein et al 2004) – naratriptan (1 mg bid for 5 days 
starting 2 days prior to the expected onset of menses) and 
frovatriptan (2.5 mg bid given for 6 days perimenstrually). 
Another preventive strategy is estrogen supplementation 
to reduce the premenstrual drop of plasma estrogen levels. 
The best evidence has been achieved for estradiol gel 
1.5 mg and transdermal estradiol 100 μg given for 7 days 
perimenstrually (De Lignieres et al 1986; Smits et al 1994). 
There is evidence that some women responding to estrogen 
supplements develop a delayed attack when estrogens are 
discontinued. Clinical practice suggests that these women 
may beneﬁ  t from an extension of estrogen supplementation 
until Day 7 of the cycle with tapering the dose over the last 
2 days (MacGregor 2007a). Suppression of the menstrual 
cycle with continuous 3- or 6-month treatment with con-
traceptive agents inhibiting ovulation is another option in 
women who take a contraceptive pill. A variety of other 
treatments have been studied including magnesium and 
pyridoxine, but the quality of evidence for their use is poor 
(see Pringsheim et al 2008).
Migraine during pregnancy
In general, women can be reassured that migraine, either 
with or without aura, does not have any adverse effects 
on the outcome of pregnancy in otherwise healthy women 
(MacGregor 2007b). As a general rule, pregnancy from 
the second trimester onwards is accompanied by marked 
improvement or disappearance of migraine without aura, but 
not of migraine with aura. There are no speciﬁ  c clinical trials 
evaluating drug treatment of migraine during pregnancy, 
but most of the anti-migraine drugs are contraindicated. 
If necessary, paracetamol and metoclopramide can be used 
during pregnancy for the acute treatment (Evers et al 2006), 
and riboﬂ  avin or non-drug therapies for prevention.
Migraine in children and adolescents
For children (age 6 years), ibuprofen (10 mg/kg body 
weight) and paracetamol (15 mg/kg body weight) are 
effective and either can be considered for the acute treatment 
of migraine (Evers et al 2001). For adolescents (12 years 
of age), sumatriptan nasal spray is effective and should 
be considered as an acute treatment (Winner et al 2000). 
For migraine prophylaxis, riboﬂ  avin is a ﬁ  rst choice in 
our experience and there is evidence of effectiveness for 
ﬂ  unarizine 5 to 10 mg/day and propranolol 40 to 80 mg/day 
(Lewis et al 2004; Evers 1999). Other drugs have not been 
studied or did not show efﬁ  cacy in appropriate studies.
Medication-overuse headache (MOH)
The most efﬁ  cient treatment for MOH is abrupt drug withdrawal 
and immediate prescription of a preventive anti-migraine drug, 
but there are no studies comparing different strategies. There 
are thus no clear, world-wide accepted guidelines regarding 
modality of withdrawal or treatment of withdrawal symptoms. 
Oral prednisone (Krymchantowski and Barbosa 2000), 
tizanidine (Smith 2002), clomipramine (Lenarduzzi et al 1988), 
and intravenous dihydroergotamine (Raskin 1986) were found 
useful for withdrawal headaches, but only prednisone has been 
investigated in two proper randomized, placebo-controlled 
trials of which one showed positive results (Pageler et al 2008) 
while the other was negative (Bøe et al 2007).
Emerging therapies for migraine
Acute treatment
As triptans are contraindicated in patients with cardio-vascular 
disorders, non-vasoconstricting agents are the holy grail in 
acute therapy research. Sserotonin 5-HT1F receptor agonists 
are currently being investigated in a phase II study in acute 
migraine, after a first compound LY334,370 was found 
effective (Goldstein et al 2001) but withdrawn because of 
animal toxicity problems. BIBN4096BS is a potent CGRP 
receptor blocker that inhibits trigeminocervical neurons and 
has been shown to be effective intravenously (as well or better 
than oral sumatriptan) (Olesen et al 2004). A novel CGRP 
antagonist, in an oral form, was found as effective as rizatriptan 
10 mg in terms of achieving pain freedom at 2 h, and seemed 
even more effective for providing sustained freedom from pain Neuropsychiatric Disease and Treatment 2008:4(6) 1053
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(Ho et al 2008). In line with a role for nitric oxide (NO) in 
migraine pathophysiology, NO synthase (NOS) inhibition was 
shown to abort acute migraine in a small study (Lassen et al 
1997) and more trials are in progress (see Goadsby 2007b for 
a review). An AMPA/kainate receptor antagonist was found 
effective in a triple-blind, placebo-controlled trial (Sang et al 
2004). A vanilloid receptor antagonist (TRPV1), SB705498, 
was studied in a randomized, placebo-controlled crossover 
study in acute migraine (NCT00269022). This study has been 
terminated, but as yet no results are in the public domain.
Preventive treatment
Ayata et al (2006) have found in rat that several prophylactic 
anti-migraine agents (topiramate, valproate, DL-propranolol, 
amitriptyline and methysergide) inhibit cortical spreading 
depression (CSD) after chronic administration. They suggested 
that CSD inhibition might be a common mode of action of 
drugs effective in migraine prevention, which is provocative 
and thought-provoking for several reasons (see Schoenen 
2006 for discussion): (i) there is no clinical evidence that CSD 
occurs in migraine without aura; (ii) all compounds in Ayata 
et al’s study were administered in very high doses compared 
to those used in migraine treatment; (iii) and ﬁ  nally, no 
genetic mutation able to modify the CSD threshold has been 
identiﬁ  ed in the common forms of migraine. Nevertheless, 
cortical spreading depression (CSD) provides a possible target 
mechanism for the laboratory-based development of new 
migraine medicines. Unfortunately, a gap-junction blocker, 
tonabersat (SB-220453) which in animal models inhibits 
neurogenic inﬂ  ammation, blocks propagation of CSD and 
inhibits trigeminal nerve ganglion stimulation-induced carotid 
vasodilatation, had a poor therapeutic gain of 17% in a random-
ized placebo-controlled phase II study (Goadsby et al 2007). 
Preliminary study reports have shown an effect of memantine 
in migraine (Cammarata and Krusz 2005; Spengos et al 2008). 
This is supported by a recent experimental study (Peeters et al 
2007), which demonstrated that different NMDA receptor 
antagonists, including memantine, decrease dose-dependently 
cortical spreading depression (CSD).
Occipital nerve stimulation (ONS) seems a promising 
approach in migraine prevention (Matharu et al 2004) especially 
in patients who are refractory to drug treatments or do not 
tolerate them. Randomized trials of ONS in chronic migraine 
are ongoing. This technique has also proved encouraging 
in other primary headache disorders such as chronic cluster 
headache (Burns et al 2007; Magis et al 2007). Vagus nerve 
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stimulation was found effective in several case reports (Sadler 
et al 2002; Mauskop 2005) and deserves further trials.
Patent foramen ovale is more prevalent in migraine with 
aura than in migraine without aura where its prevalence 
is comparable to that of the general population. Several 
retrospective and uncontrolled studies suggest that 
percutaneous closure of a patent foramen ovale (PFO) 
for cryptogenic stroke or decompression illness in divers 
reduces frequency of migraine attacks with, but also without 
aura. In one multicenter, prospective, placebo- controlled 
trial (MIST) the primary outcome measure, disappearance 
of migraine attacks, was not achieved, but there might be 
some improvement in attack frequency. Other controlled 
trials are underway and as long as their results are not 
known, there is no rationale for proposing PFO closure for 
migraine (see Schoenen et al 2006 for an extensive review 
and discussion).
To conclude, migraine is a common disorder of the brain 
which causes considerable disability. Various effective 
therapies are available, but there is room for improvement in 
acute-attack medicines, and a similar need for more efﬁ  cient 
and better tolerable preventive approaches. A better knowledge 
of pathogenic mechanisms through research is mandatory 
before this can be achieved. Meanwhile, new emerging 
symptomatic treatments create new hope for patients and may 
contribute to decrease the burden of the disorder.
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